High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis

Neoplasia (United States)

Volumn 14, Issue 9, 2012, Pages 788-798

  Diaz, Roberto Jose ^a,b   Guduk, Mustafa ^c   Romagnuolo, Rocco ^a   Smith, Christian A ^a   Northcott, Paul ^a   Shih, David ^a   Berisha, Fitim ^d   Flanagan, Adrienne ^d,e   Munoz, David G ^f   Cusimano, Michael D ^b,g   Pamir, M Necmettin ^c   Rutka, James T ^a,b,g  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ACIBADEM UNIVERSITY   (Turkey)

^d ROYAL NATIONAL ORTHOPAEDIC HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN MTAP; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANEUPLOIDY; ARTICLE; CHILD; CHORDOMA; CHROMOSOME 3; CHROMOSOME 9P; CHROMOSOME ADDITION; CHROMOSOME LOSS; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE LOSS; GENE REGULATORY NETWORK; GENETIC REGULATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SKULL BASE TUMOR; TISSUE MICROARRAY;

EID: 84866566005     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12526     Document Type: Article

References (77)

1. McMaster ML, Goldstein AM, Bromley CM, Ishibe N, and Parry DM (2001). Chordoma: incidence and survival patterns in the United States, 1973-1995. Cancer Causes Control 12, 1-11.
2. Dorfman HD and Czerniak B (1995). Bone cancers. Cancer 75, 203-210.
3. Eriksson B, Gunterberg B, and Kindblom LG (1981). Chordoma. A clinicopathologic and prognostic study of a Swedish national series. Acta Orthop Scand 52, 49-58.
4. Higinbotham NL, Phillips RF, Farr HW, and Hustu HO (1967). Chordoma. Thirty-five-year study at Memorial Hospital. Cancer 20, 1841-1850.
5. Catton C, O'Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, and Wunder J (1996). Chordoma: long-termfollow-up after radical photon irradiation. Radiother Oncol 41, 67-72.
6. Chambers PW and Schwinn CP (1979). Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol 72, 765-776.
7. Baratti D, Gronchi A, Pennacchioli E, Lozza L, Colecchia M, Fiore M, and Santinami M (2003). Chordoma: natural history and results in 28 patients treated at a single institution. Ann Surg Oncol 10, 291-296.
8. Diaz RJ and Cusimano MD (2011). The biological basis for modern treatment of chordoma. J Neurooncol 104, 411-422.
9. Ares C, Hug EB, Lomax AJ, Bolsi A, Timmermann B, Rutz HP, Schuller JC, Pedroni E, and Goitein G (2009). Effectiveness and safety of spot scanning proton radiation therapy for chordomas and chondrosarcomas of the skull base: first long-term report. Int J Radiat Oncol Biol Phys 75, 1111-1118.
10. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammar H, Haie-Meder C, Ponvert D, Hasboun D, Ferrand R, Nauraye C, et al. (2005). Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. Acta Oncol 44, 700-708.
11. Almefty KK, Pravdenkova S, Sawyer J, and Al-Mefty O (2009). Impact of cytogenetic abnormalities on the management of skull base chordomas. J Neurosurg 110, 715-724.
12. Hallor KH, Staaf J, Jonsson G, Heidenblad M, Vult von Steyern F, Bauer HC, Ijszenga M, Hogendoorn PC, Mandahl N, Szuhai K, et al. (2008). Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisation. Br J Cancer 98, 434-442.
13. Longoni M, Orzan F, Stroppi M, Boari N, Mortini P, and Riva P (2008). Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study. Neuro Oncol 10, 52-60.
14. Sawyer JR, Husain M, and Al-Mefty O (2001). Identification of isochromosome 1q as a recurring chromosome aberration in skull base chordomas: a new marker for aggressive tumors? Neurosurg Focus 10, E6.
15. Bayrakli F, Guney I, Kilic T, Ozek M, and Pamir MN (2007). New candidate chromosomal regions for chordoma development. Surg Neurol 68, 425-430; discussion 430.
16. Eisenberg MB, Woloschak M, Sen C, and Wolfe D (1997). Loss of heterozygosity in the retinoblastoma tumor suppressor gene in skull base chordomas and chondrosarcomas. Surg Neurol 47, 156-160; discussion 160-151.
17. Gil Z, Fliss DM, Voskoboinik N, Leider-Trejo L, Spektor S, Yaron Y, and Orr-Urtreger A (2004). Cytogenetic analysis of three variants of clival chordoma. Cancer Genet Cytogenet 154, 124-130.
18. Kuzniacka A, Mertens F, Strombeck B, Wiegant J, and Mandahl N (2004). Combined binary ratio labeling fluorescence in situ hybridization analysis of chordoma. Cancer Genet Cytogenet 151, 178-181.
19. Scheil S, Bruderlein S, Liehr T, Starke H, Herms J, Schulte M, and Moller P (2001). Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1. Genes Chromosomes Cancer 32, 203-211.
20. Long F, Sun W, Ji X, Li XH, Liu XQ, Jiang WT, and Tao J (2011). Clinical application of multiplex ligation-dependent probe amplification for the detection exonic copy number alterations in the Dystrophin gene. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28, 699-704.
21. Heffelfinger MJ, Dahlin DC, MacCarty CS, and Beabout JW (1973). Chordomas and cartilaginous tumors at the skull base. Cancer 32, 410-420.
22. Rosenberg AE, Brown GA, Bhan AK, and Lee JM (1994). Chondroid chordoma-a variant of chordoma. A morphologic and immunohistochemical study. Am J Clin Pathol 101, 36-41.
23. Northcott PA, Nakahara Y, Wu X, Feuk L, Ellison DW, Croul S, Mack S, Kongkham PN, Peacock J, Dubuc A, et al. (2009). Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nat Genet 41, 465-472.
24. Li C and Wong WH (2001).Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98, 31-36.
25. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, and Li C (2004). dChipSNP: significance curve and clustering of SNP-array-based loss-ofheterozygosity data. Bioinformatics 20, 1233-1240.
26. Yamamoto G, Nannya Y, Kato M, Sanada M, Levine RL, Kawamata N, Hangaishi A, Kurokawa M, Chiba S, Gilliland DG, et al. (2007). Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of Affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81, 114-126.
27. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, Shago M, Moessner R, Pinto D, Ren Y, et al. (2008). Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82, 477-488.
28. Venkatraman ES and Olshen AB (2007). A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657-663.
29. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, and Mesirov JP (2011). Integrative genomics viewer. Nat Biotechnol 29, 24-26.
30. Pamir MN and Ozduman K (2008). Tumor-biology and current treatment of skull-base chordomas. Adv Tech Stand Neurosurg 33, 35-129.
31. Hruban RH, Traganos F, Reuter VE, and Huvos AG (1990). Chordomas with malignant spindle cell components. A DNA flow cytometric and immunohistochemical study with histogenetic implications. Am J Pathol 137, 435-447.
32. Schoedel KE, Martinez AJ, Mahoney TM, Contis L, and Becich MJ (1995). Chordomas: pathological features; ploidy and silver nucleolar organizing region analysis. A study of 36 cases. Acta Neuropathol 89, 139-143.
33. Le LP, Nielsen GP, Rosenberg AE, Thomas D, Batten JM, Deshpande V, Schwab J, Duan Z, Xavier RJ, Hornicek FJ, et al. (2011). Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS One 6, e18846.
34. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, et al. (2011). Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 223, 327-335.
35. Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman NI, Kosztowski TA, Awad OA, McCarthy EF, Loeb DM, et al. (2011). Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target. J Neurosurg 115, 760-769.
36. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, Li S, Goldstein AM, Parry DM, and Kelley MJ (2009). T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41, 1176-1178.
37. Aydemir E, Bayrak OF, Sahin F, Atalay B, Kose GT, Ozen M, Sevli S, Dalan AB, Yalvac ME, Dogruluk T, et al. (2012). Characterization of cancer stem-like cells in chordoma. J Neurosurg 116, 810-820.
38. Sozzi G, Tornielli S, Tagliabue E, Sard L, Pezzella F, Pastorino U, Minoletti F, Pilotti S, Ratcliffe C, Veronese ML, et al. (1997). Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res 57, 5207-5212.
39. Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV, et al. (1997). FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57, 2256-2267.
40. Naylor SL, Johnson BE, Minna JD, and Sakaguchi AY (1987). Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329, 451-454.
41. Hibi K, Takahashi T, Yamakawa K, Ueda R, Sekido Y, Ariyoshi Y, Suyama M, Takagi H, and Nakamura Y (1992). Three distinct regions involved in 3p deletion in human lung cancer. Oncogene 7, 445-449.
42. Yamakawa K, Morita R, Takahashi E, Hori T, Ishikawa J, and Nakamura Y (1991). A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res 51, 4707-4711.
43. Maestro R, Gasparotto D, Vukosavljevic T, Barzan L, Sulfaro S, and Boiocchi M (1993). Three discrete regions of deletion at 3p in head and neck cancers. Cancer Res 53, 5775-5779.
44. Kohno T, Takayama H, Hamaguchi M, Takano H, Yamaguchi N, Tsuda H, Hirohashi S, Vissing H, Shimizu M, Oshimura M, et al. (1993). Deletion mapping of chromosome 3p in human uterine cervical cancer. Oncogene 8, 1825-1832.
45. Sato T, Akiyama F, Sakamoto G, Kasumi F, and Nakamura Y (1991). Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 51, 5794-5799.
46. Ong ST, Fong KM, Bader SA, Minna JD, Le Beau MM, McKeithan TW, and Rassool FV (1997). Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletionswithin FRA3B that affect FHIT transcription in tumor cell lines. Genes Chromosomes Cancer 20, 16-23.
47. Huebner K, Hadaczek P, Siprashvili Z, Druck T, and Croce CM (1997). The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta 1332, M65-M70.
48. Zawacka-Pankau J and Ferens B (2009). Enlightened protein: Fhit tumor suppressor protein structure and function and its role in the toxicity of protoporphyrin IXmediated photodynamic reaction. Toxicol Appl Pharmacol 241, 246-252.
49. Ozeri-Galai E, Bester AC, and Kerem B (2012). The complex basis underlying common fragile site instability in cancer. Trends Genet 28, 295-302.
50. Letessier A, Millot GA, Koundrioukoff S, Lachages AM, Vogt N, Hansen RS, Malfoy B, Brison O, and Debatisse M (2011). Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature 470, 120-123.
51. Wang L, Darling J, Zhang JS, Huang H, Liu W, and Smith DI (1999). Allelespecific late replication and fragility of the most active common fragile site, FRA3B. Hum Mol Genet 8, 431-437.
52. Palakodeti A, Lucas I, Jiang Y, Young DJ, Fernald AA, Karrison T, and Le Beau MM (2010). Impaired replication dynamics at the FRA3B common fragile site. Hum Mol Genet 19, 99-110.
53. Helmrich A, Ballarino M, and Tora L (2011). Collisions between replication and transcription complexes cause common fragile site instability at the longest human genes. Mol Cell 44, 966-977.
54. Birnbaum DJ, Adelaide J, Mamessier E, Finetti P, Lagarde A, Monges G, Viret F, Goncalves A, Turrini O, Delpero JR, et al. (2011). Genome profiling of pancreatic adenocarcinoma. Genes Chromosomes Cancer 50, 456-465.
55. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, and Croce CM (1996). FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 93, 9770-9775.
56. Michael D, Beer DG, Wilke CW, Miller DE, and Glover TW (1997). Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 15, 1653-1659.
57. Sukosd F, Kuroda N, Beothe T, Kaur AP, and Kovacs G (2003). Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 63, 455-457.
58. Cecener G, Tunca B, Egeli U, Bekar A, Guler G, Tolunay S, and Aksoy K (2010). FHIT gene sequence variants and reduced Fhit protein expression in glioblastoma multiforme. Cell Mol Neurobiol 30, 301-307.
59. Gatalica Z, Lele SM, Rampy BA, and Norris BA (2000). The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma. Cancer 88, 1378-1383.
60. Hayashi S, Tanimoto K, Hajiro-Nakanishi K, Tsuchiya E, Kurosumi M, Higashi Y, Imai K, Suga K, and Nakachi K (1997). Abnormal FHIT transcripts in human breast carcinomas: a clinicopathological and epidemiological analysis of 61 Japanese cases. Cancer Res 57, 1981-1985.
61. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM, and Huebner K (2001). The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci USA 98, 10250-10255.
62. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, and Huebner K (1996). Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5′″-P1,P3-triphosphate hydrolase. Biochemistry 35, 11529-11535.
63. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, et al. (1997). Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94, 13771-13776.
64. Ji L, Fang B, Yen N, Fong K, Minna JD, and Roth JA (1999). Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59, 3333-3339.
65. Nishizaki M, Sasaki J, Fang B, Atkinson EN, Minna JD, Roth JA, and Ji L (2004). Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human nonsmall cell lung cancer cells. Cancer Res 64, 5745-5752.
66. Ishii H, Wang Y, and Huebner K (2007). A Fhit-ing role in the DNA damage checkpoint response. Cell Cycle 6, 1044-1048.
67. Ishii H, Mimori K, Inoue H, Inageta T, Ishikawa K, Semba S, Druck T, Trapasso F, Tani K, Vecchione A, et al. (2006). Fhit modulates the DNA damage checkpoint response. Cancer Res 66, 11287-11292.
68. Rimessi A, Marchi S, Fotino C, Romagnoli A, Huebner K, Croce CM, Pinton P, and Rizzuto R (2009). Intramitochondrial calcium regulation by the FHIT gene product sensitizes to apoptosis. Proc Natl Acad Sci USA 106, 12753-12758.
69. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, et al. (1997). Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57, 504-512.
70. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, and Minna JD (2001). 5′ CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61, 3581-3585.
71. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk YM, Rynditch AV, and Vozianov AF (2008). Hypermethylation of the 5′ CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett 265, 250-257.
72. Tanaka H, Shimada Y, Harada H, Shinoda M, Hatooka S, Imamura M, and Ishizaki K (1998). Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res 58, 3429-3434.
73. Hu B, Han SY, Wang X, Ottey M, Potoczek MB, Dicker A, Huebner K, and Wang Y (2005). Involvement of the Fhit gene in the ionizing radiation-activated ATR/CHK1 pathway. J Cell Physiol 202, 518-523.
74. Zandi R, Xu K, Poulsen HS, Roth JA, and Ji L (2011). The effect of adenovirusmediated gene expression of FHIT in small cell lung cancer cells. Cancer Invest 29, 683-691.
75. Sevignani C, Calin GA, Cesari R, Sarti M, Ishii H, Yendamuri S, Vecchione A, Trapasso F, and Croce CM (2003). Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines. Cancer Res 63, 1183-1187.
76. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K, et al. (2001). Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61, 1578-1584.
77. Dumon KR, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato EF, Williams NN, Baffa R, et al. (2001). Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer. Cancer Res 61, 4827-4836.